Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy

Pui Yan Ho, Zhijian Duan, Neelu Batra, Joseph L. Jilek, Mei Juan Tu, Jing Xin Qiu, Zihua Hu, Theodore Wun, Primo N Lara, Ralph W deVere White, Hongwu Chen, Aiming Yu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Noncoding RNAs (ncRNAs) produced in live cells may better reflect intracellular ncRNAs for research and therapy. Attempts were made to produce biologic ncRNAs, but at low yield or success rate. Here we first report a new ncRNA bioengineering technology using more stable ncRNA carrier (nCAR) containing a pre-miR-34a derivative identified by rational design and experimental validation. This approach offered a remarkable higher level expression (40%–80% of total RNAs) of recombinant ncRNAs in bacteria and gave an 80% success rate (33 of 42 ncRNAs). New FPLC and spin-column based methods were also developed for large- and small-scale purification of milligrams and micrograms of recombinant ncRNAs from half liter and milliliters of bacterial culture, respectively. We then used two bioengineered nCAR/miRNAs to demonstrate the selective release of target miRNAs into human cells, which were revealed to be Dicer dependent (miR-34a-5p) or independent (miR-124a-3p), and subsequent changes of miRNome and transcriptome profiles. miRNA enrichment analyses of altered transcriptome confirmed the specificity of nCAR/miRNAs in target gene regulation. Furthermore, nCAR assembled miR-34a-5p and miR-124-3p were active in suppressing human lung carcinoma cell proliferation through modulation of target gene expression (e.g., cMET and CDK6 for miR-34a-5p; STAT3 and ABCC4 for miR-124-3p). In addition, bioengineered miRNA molecules were effective in controlling metastatic lung xenograft progression, as demonstrated by live animal and ex vivo lung tissue bioluminescent imaging as well as histopathological examination. This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)494-506
Number of pages13
JournalJournal of Pharmacology and Experimental Therapeutics
Volume365
Issue number3
DOIs
StatePublished - Jun 1 2018

Fingerprint

Untranslated RNA
MicroRNAs
Neoplasms
Bioengineering
Lung
Therapeutics
Gene Expression Profiling
Transcriptome
Heterografts
Research Design
Cell Proliferation
Technology
Bacteria
Carcinoma
Gene Expression
Research
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy. / Ho, Pui Yan; Duan, Zhijian; Batra, Neelu; Jilek, Joseph L.; Tu, Mei Juan; Qiu, Jing Xin; Hu, Zihua; Wun, Theodore; Lara, Primo N; deVere White, Ralph W; Chen, Hongwu; Yu, Aiming.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 365, No. 3, 01.06.2018, p. 494-506.

Research output: Contribution to journalArticle

@article{230f385358e24f46afea7f02c3ad8f82,
title = "Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy",
abstract = "Noncoding RNAs (ncRNAs) produced in live cells may better reflect intracellular ncRNAs for research and therapy. Attempts were made to produce biologic ncRNAs, but at low yield or success rate. Here we first report a new ncRNA bioengineering technology using more stable ncRNA carrier (nCAR) containing a pre-miR-34a derivative identified by rational design and experimental validation. This approach offered a remarkable higher level expression (40{\%}–80{\%} of total RNAs) of recombinant ncRNAs in bacteria and gave an 80{\%} success rate (33 of 42 ncRNAs). New FPLC and spin-column based methods were also developed for large- and small-scale purification of milligrams and micrograms of recombinant ncRNAs from half liter and milliliters of bacterial culture, respectively. We then used two bioengineered nCAR/miRNAs to demonstrate the selective release of target miRNAs into human cells, which were revealed to be Dicer dependent (miR-34a-5p) or independent (miR-124a-3p), and subsequent changes of miRNome and transcriptome profiles. miRNA enrichment analyses of altered transcriptome confirmed the specificity of nCAR/miRNAs in target gene regulation. Furthermore, nCAR assembled miR-34a-5p and miR-124-3p were active in suppressing human lung carcinoma cell proliferation through modulation of target gene expression (e.g., cMET and CDK6 for miR-34a-5p; STAT3 and ABCC4 for miR-124-3p). In addition, bioengineered miRNA molecules were effective in controlling metastatic lung xenograft progression, as demonstrated by live animal and ex vivo lung tissue bioluminescent imaging as well as histopathological examination. This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics.",
author = "Ho, {Pui Yan} and Zhijian Duan and Neelu Batra and Jilek, {Joseph L.} and Tu, {Mei Juan} and Qiu, {Jing Xin} and Zihua Hu and Theodore Wun and Lara, {Primo N} and {deVere White}, {Ralph W} and Hongwu Chen and Aiming Yu",
year = "2018",
month = "6",
day = "1",
doi = "10.1124/jpet.118.247775",
language = "English (US)",
volume = "365",
pages = "494--506",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Bioengineered noncoding RNAs selectively change cellular miRNome profiles for cancer therapy

AU - Ho, Pui Yan

AU - Duan, Zhijian

AU - Batra, Neelu

AU - Jilek, Joseph L.

AU - Tu, Mei Juan

AU - Qiu, Jing Xin

AU - Hu, Zihua

AU - Wun, Theodore

AU - Lara, Primo N

AU - deVere White, Ralph W

AU - Chen, Hongwu

AU - Yu, Aiming

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Noncoding RNAs (ncRNAs) produced in live cells may better reflect intracellular ncRNAs for research and therapy. Attempts were made to produce biologic ncRNAs, but at low yield or success rate. Here we first report a new ncRNA bioengineering technology using more stable ncRNA carrier (nCAR) containing a pre-miR-34a derivative identified by rational design and experimental validation. This approach offered a remarkable higher level expression (40%–80% of total RNAs) of recombinant ncRNAs in bacteria and gave an 80% success rate (33 of 42 ncRNAs). New FPLC and spin-column based methods were also developed for large- and small-scale purification of milligrams and micrograms of recombinant ncRNAs from half liter and milliliters of bacterial culture, respectively. We then used two bioengineered nCAR/miRNAs to demonstrate the selective release of target miRNAs into human cells, which were revealed to be Dicer dependent (miR-34a-5p) or independent (miR-124a-3p), and subsequent changes of miRNome and transcriptome profiles. miRNA enrichment analyses of altered transcriptome confirmed the specificity of nCAR/miRNAs in target gene regulation. Furthermore, nCAR assembled miR-34a-5p and miR-124-3p were active in suppressing human lung carcinoma cell proliferation through modulation of target gene expression (e.g., cMET and CDK6 for miR-34a-5p; STAT3 and ABCC4 for miR-124-3p). In addition, bioengineered miRNA molecules were effective in controlling metastatic lung xenograft progression, as demonstrated by live animal and ex vivo lung tissue bioluminescent imaging as well as histopathological examination. This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics.

AB - Noncoding RNAs (ncRNAs) produced in live cells may better reflect intracellular ncRNAs for research and therapy. Attempts were made to produce biologic ncRNAs, but at low yield or success rate. Here we first report a new ncRNA bioengineering technology using more stable ncRNA carrier (nCAR) containing a pre-miR-34a derivative identified by rational design and experimental validation. This approach offered a remarkable higher level expression (40%–80% of total RNAs) of recombinant ncRNAs in bacteria and gave an 80% success rate (33 of 42 ncRNAs). New FPLC and spin-column based methods were also developed for large- and small-scale purification of milligrams and micrograms of recombinant ncRNAs from half liter and milliliters of bacterial culture, respectively. We then used two bioengineered nCAR/miRNAs to demonstrate the selective release of target miRNAs into human cells, which were revealed to be Dicer dependent (miR-34a-5p) or independent (miR-124a-3p), and subsequent changes of miRNome and transcriptome profiles. miRNA enrichment analyses of altered transcriptome confirmed the specificity of nCAR/miRNAs in target gene regulation. Furthermore, nCAR assembled miR-34a-5p and miR-124-3p were active in suppressing human lung carcinoma cell proliferation through modulation of target gene expression (e.g., cMET and CDK6 for miR-34a-5p; STAT3 and ABCC4 for miR-124-3p). In addition, bioengineered miRNA molecules were effective in controlling metastatic lung xenograft progression, as demonstrated by live animal and ex vivo lung tissue bioluminescent imaging as well as histopathological examination. This novel ncRNA bioengineering platform can be easily adapted to produce various ncRNA molecules, and biologic ncRNAs hold the promise as new cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85046652293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046652293&partnerID=8YFLogxK

U2 - 10.1124/jpet.118.247775

DO - 10.1124/jpet.118.247775

M3 - Article

C2 - 29602831

AN - SCOPUS:85046652293

VL - 365

SP - 494

EP - 506

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -